Logo image of UTHR

UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis

NASDAQ:UTHR - Nasdaq - US91307C1027 - Common Stock - Currency: USD

286.88  -1.68 (-0.58%)

After market: 286.88 0 (0%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to UTHR. UTHR was compared to 557 industry peers in the Biotechnology industry. UTHR scores excellent points on both the profitability and health parts. This is a solid base for a good stock. UTHR is valued quite cheap, while showing a decent growth score. This is a good combination! This makes UTHR very considerable for value and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

UTHR had positive earnings in the past year.
UTHR had a positive operating cash flow in the past year.
UTHR had positive earnings in each of the past 5 years.
UTHR had a positive operating cash flow in each of the past 5 years.
UTHR Yearly Net Income VS EBIT VS OCF VS FCFUTHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

UTHR's Return On Assets of 15.63% is amongst the best of the industry. UTHR outperforms 96.23% of its industry peers.
UTHR has a better Return On Equity (17.79%) than 96.05% of its industry peers.
Looking at the Return On Invested Capital, with a value of 16.27%, UTHR belongs to the top of the industry, outperforming 96.95% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for UTHR is in line with the industry average of 14.78%.
The last Return On Invested Capital (16.27%) for UTHR is above the 3 year average (14.96%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 15.63%
ROE 17.79%
ROIC 16.27%
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
UTHR Yearly ROA, ROE, ROICUTHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

UTHR's Profit Margin of 40.44% is amongst the best of the industry. UTHR outperforms 98.56% of its industry peers.
UTHR's Profit Margin has improved in the last couple of years.
UTHR has a Operating Margin of 49.25%. This is amongst the best in the industry. UTHR outperforms 99.64% of its industry peers.
UTHR's Operating Margin has improved in the last couple of years.
UTHR has a Gross Margin of 89.00%. This is amongst the best in the industry. UTHR outperforms 91.56% of its industry peers.
In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
Industry RankSector Rank
OM 49.25%
PM (TTM) 40.44%
GM 89%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
UTHR Yearly Profit, Operating, Gross MarginsUTHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so UTHR is creating value.
Compared to 1 year ago, UTHR has less shares outstanding
The number of shares outstanding for UTHR has been increased compared to 5 years ago.
Compared to 1 year ago, UTHR has an improved debt to assets ratio.
UTHR Yearly Shares OutstandingUTHR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
UTHR Yearly Total Debt VS Total AssetsUTHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 11.22 indicates that UTHR is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.22, UTHR belongs to the top of the industry, outperforming 88.51% of the companies in the same industry.
UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.18
Altman-Z 11.22
ROIC/WACC1.81
WACC8.99%
UTHR Yearly LT Debt VS Equity VS FCFUTHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

A Current Ratio of 5.46 indicates that UTHR has no problem at all paying its short term obligations.
The Current ratio of UTHR (5.46) is comparable to the rest of the industry.
UTHR has a Quick Ratio of 5.23. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of UTHR (5.23) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.46
Quick Ratio 5.23
UTHR Yearly Current Assets VS Current LiabilitesUTHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

5

3. Growth

3.1 Past

UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.49%, which is quite good.
Measured over the past years, UTHR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 16.88% on average per year.
Looking at the last year, UTHR shows a quite strong growth in Revenue. The Revenue has grown by 19.85% in the last year.
The Revenue has been growing by 14.71% on average over the past years. This is quite good.
EPS 1Y (TTM)18.49%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%7.46%
Revenue 1Y (TTM)19.85%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%17.22%

3.2 Future

The Earnings Per Share is expected to grow by 12.95% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.48% on average over the next years.
EPS Next Y14.68%
EPS Next 2Y8.6%
EPS Next 3Y5.67%
EPS Next 5Y12.95%
Revenue Next Year12.38%
Revenue Next 2Y9.18%
Revenue Next 3Y7.29%
Revenue Next 5Y7.48%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
UTHR Yearly Revenue VS EstimatesUTHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
UTHR Yearly EPS VS EstimatesUTHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30 40 50

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 11.45, which indicates a very decent valuation of UTHR.
Based on the Price/Earnings ratio, UTHR is valued cheaply inside the industry as 96.77% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.57, UTHR is valued rather cheaply.
With a Price/Forward Earnings ratio of 9.89, the valuation of UTHR can be described as very reasonable.
Based on the Price/Forward Earnings ratio, UTHR is valued cheaper than 96.59% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of UTHR to the average of the S&P500 Index (22.41), we can say UTHR is valued rather cheaply.
Industry RankSector Rank
PE 11.45
Fwd PE 9.89
UTHR Price Earnings VS Forward Price EarningsUTHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

UTHR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. UTHR is cheaper than 98.74% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 96.23% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 11.47
EV/EBITDA 5.46
UTHR Per share dataUTHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of UTHR may justify a higher PE ratio.
PEG (NY)0.78
PEG (5Y)0.68
EPS Next 2Y8.6%
EPS Next 3Y5.67%

More info and screens

0

5. Dividend

5.1 Amount

UTHR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNITED THERAPEUTICS CORP

NASDAQ:UTHR (6/17/2025, 5:20:02 PM)

After market: 286.88 0 (0%)

286.88

-1.68 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)07-29 2025-07-29/amc
Inst Owners101.36%
Inst Owner Change-28.12%
Ins Owners1.75%
Ins Owner Change-11.82%
Market Cap12.94B
Analysts79
Price Target399.49 (39.25%)
Short Float %4.24%
Short Ratio3.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.14%
Min EPS beat(2)-3.83%
Max EPS beat(2)-0.45%
EPS beat(4)0
Avg EPS beat(4)-4.28%
Min EPS beat(4)-10.35%
Max EPS beat(4)-0.45%
EPS beat(8)4
Avg EPS beat(8)1.33%
EPS beat(12)6
Avg EPS beat(12)-3.77%
EPS beat(16)8
Avg EPS beat(16)-1.5%
Revenue beat(2)1
Avg Revenue beat(2)2.45%
Min Revenue beat(2)-1.81%
Max Revenue beat(2)6.71%
Revenue beat(4)3
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-1.81%
Max Revenue beat(4)6.71%
Revenue beat(8)7
Avg Revenue beat(8)4.04%
Revenue beat(12)8
Avg Revenue beat(12)1.96%
Revenue beat(16)11
Avg Revenue beat(16)2.85%
PT rev (1m)0%
PT rev (3m)-2.59%
EPS NQ rev (1m)0.4%
EPS NQ rev (3m)2.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.13%
Revenue NQ rev (1m)0.21%
Revenue NQ rev (3m)3.18%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)2.52%
Valuation
Industry RankSector Rank
PE 11.45
Fwd PE 9.89
P/S 4.32
P/FCF 11.47
P/OCF 9.17
P/B 1.9
P/tB 1.93
EV/EBITDA 5.46
EPS(TTM)25.06
EY8.74%
EPS(NY)29.01
Fwd EY10.11%
FCF(TTM)25.02
FCFY8.72%
OCF(TTM)31.3
OCFY10.91%
SpS66.37
BVpS150.9
TBVpS148.43
PEG (NY)0.78
PEG (5Y)0.68
Profitability
Industry RankSector Rank
ROA 15.63%
ROE 17.79%
ROCE 21%
ROIC 16.27%
ROICexc 30.87%
ROICexgc 31.83%
OM 49.25%
PM (TTM) 40.44%
GM 89%
FCFM 37.69%
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexcg growth 3Y23.22%
ROICexcg growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score7
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.18
Debt/EBITDA 0
Cap/Depr 366.37%
Cap/Sales 9.46%
Interest Coverage 44.68
Cash Conversion 90.97%
Profit Quality 93.22%
Current Ratio 5.46
Quick Ratio 5.23
Altman-Z 11.22
F-Score7
WACC8.99%
ROIC/WACC1.81
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)18.49%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%7.46%
EPS Next Y14.68%
EPS Next 2Y8.6%
EPS Next 3Y5.67%
EPS Next 5Y12.95%
Revenue 1Y (TTM)19.85%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%17.22%
Revenue Next Year12.38%
Revenue Next 2Y9.18%
Revenue Next 3Y7.29%
Revenue Next 5Y7.48%
EBIT growth 1Y16.99%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year17.96%
EBIT Next 3Y3.92%
EBIT Next 5Y-4.6%
FCF growth 1Y56.32%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y58.88%
OCF growth 3Y30.42%
OCF growth 5YN/A